Thoracic Paravertebral Blocks Using a Combination of Ropivacaine and Dexmedetomidine

Sponsor
China Medical University, China (Other)
Overall Status
Withdrawn
CT.gov ID
NCT03677115
Collaborator
(none)
0
1
1
52.9
0

Study Details

Study Description

Brief Summary

The investigators designed a study to assess whether thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine prolong nerve block duration.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

The investigators designed a study to assess whether thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine prolong nerve block duration. The effects of dexmedetomidine have only been compared at lower doses. This trial examined the effect of greater dose of dexmedetomidine on thoracic paravertebral block analgesia duration.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
a single-dose thoracic paravertebral analgesia for postoperative pain control after thoracoscopic lobectomya single-dose thoracic paravertebral analgesia for postoperative pain control after thoracoscopic lobectomy
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Thoracic Paravertebral Blocks Using a Combination of Ropivacaine and Dexmedetomidine
Actual Study Start Date :
Nov 1, 2018
Anticipated Primary Completion Date :
Mar 30, 2023
Anticipated Study Completion Date :
Mar 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: dexmedetomidine group

a combination of ropivacaine and dexmedetomidine

Drug: Dexmedetomidine
combination of ropivacaine and dexmedetomidine 20 ug every time

Outcome Measures

Primary Outcome Measures

  1. Change of analgesia duration [Change from Baseline to 3 days after surgery]

    Change of thoracic paravertebral block analgesia duration

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients were included in the study if they were ethnic Chinese,

  • American Society of Anesthesiologists (ASA) physical status I or II,

  • candidates for general anesthesia undergoing thoracic surgery

Exclusion Criteria:
  • Patients were excluded if they do not want to cooperate with the test,

  • had a history of radial artery puncture or coronary artery bypass grafting,

  • had acute vessel trauma,or had been diagnosed with Raynaud' disease,

  • had suffered from mental or neurological disorders

Contacts and Locations

Locations

Site City State Country Postal Code
1 the First Hospital of China Medical University Shenyang Liaoning China 110001

Sponsors and Collaborators

  • China Medical University, China

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wen-fei Tan, Professor, China Medical University, China
ClinicalTrials.gov Identifier:
NCT03677115
Other Study ID Numbers:
  • 201707158
First Posted:
Sep 19, 2018
Last Update Posted:
Nov 12, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 12, 2021